It was reliable to use VEGFR-3 and LYVE-1 to identify the lymphatic endothelial cells.
在培养的细胞中，采用VEGFR - 3和LYVE - 1因子鉴定淋巴管内皮细胞的方法可靠。
The classification, mechanism and application of VEGF and VEGFR in anti-tumor therapy are reviewed.
本文综述了VEGF及其受体的分类、作用机制及在抗肿瘤治疗中的应用。
Angiogenesis induced by VEGF and its receptor (VEGFR) play a critical role in tumor growth and metastasis.
VEGF及其受体介导的肿瘤血管新生在肿瘤的生长和转移中具有重要的作用。
Result: The expression of VEGF and VEGFR was weak in normal nasal mucous, and very strong in nasal polyps.
结果：血管内皮生长因子及其受体在正常鼻粘膜呈弱阳性，在鼻息肉呈强阳性表达。
MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR.
孟鲁司特可能通过并影响VEGF及受体的表达影响气道炎症和气道血管重塑的病理生理过程。
The number of VEGFR-3 possive vessel is correlated with tumor size infiltration and lymph node metastasis.
阳性脉管数与肿瘤大小、浸润深度和局部淋巴结转移相关；
VEGF-C and its receptor VEGFR-2/VEGFR-3 are the key players in the molecular regulation of lymphangiogenesis.
VEGF-C主要通过其受体VEGFR-2、VEGFR-3发挥作用，是一种重要的血管、淋巴管内皮细胞调节因子。
Results VEGFR-3 were expressed in lymphatic endothelium, vascular endothelium and 38% of gastric cancer cells.
结果淋巴管内皮、血管内皮及部分（38%）胃癌细胞均可表达VEGFR-3蛋白。
Undifferentiated human embryonic stem cells express VEGFR-2, and VEGFR-2 expression persists on differentiation.
未分化人胚胎干细胞表达VEGFR - 2，并在分化时持续表达。
Results There was no expression of VEGF-C in normal colorectal tissues, but VEGFR-3 expressed in the lymphatic endothelium.
结果正常大肠组织内未见VEGF - C阳性表达，但可见淋巴管内皮细胞VEGFR - 3阳性表达。
Conclusions: Kanglaite Injection can inhibit tumor angiopoiesis, its mechanism and regulate related to VEGF/VEGFR-2 signal conduct.
结论：康莱特能在一定程度上抑制肿瘤血管生成，其作用机制与调控VEGF／VEGFR-2信号传导有关。
The normal expression of VEGFR is right kidney spherule development, reach its of normal structure and function maintain very necessary.
VEGFR的正常表达对肾小球发育，及其正常结构和功能的维持都十分必要。
Conclusion The expressions of VEGFR-3 and VEGF-C in breast cancer have close relations with lymph node metastasis and clinical TNM stages.
结论VEGFR - 3和vegf - C在乳腺癌中的表达与肿瘤临床分期及淋巴结转移的关系密切。
AIM: to explore the expression of vascular endothelial growth factor receptor (VEGFR) KDR and its relation with microvessel density (MVD).
前言：目的：研究骨肉瘤中血管内皮生长因子受体(VEG FR 2)KDR的表达情况，及其与微血管密度(MVD)关系。
It appears that PKC inhibitors act on similar and, in some instances, distinct pathways compared to those of the EGFR and VEGFR inhibitors.
PK C抑制剂似乎以相同的方式发挥作用，在某些情况下与那些EGFR和VEGFR抑制剂比较，却有不同的作用途径。
Conclusion VEGFR-3 expression in different places in gastric cancer have the double roles in lymphatic metastasis and hematogenous metastasis.
结论胃癌组织vegfr - 3不同定位的表达在胃癌血道转移和淋巴道转移过程中发挥了双重作用。
TP subgroup analysis found that VEGFR-2 positive patients was positively correlated with the TNM stage, and there is statistical significance.
亚组分析发现TP阳性的患者中vegfr - 2与TNM分期成正相关，且有统计学意义。
VEGF-C/ VEGFR-3 (FLT-4) signalling which is mediated of lymphogenesis or dilation of lymphatics is closely correlated with lymphogenesis of tumor.
信号系统是淋巴管生成或扩张的信号通路，与肿瘤淋巴管的生成密切相关。
The development of EGFR and VEGFR pathway antagonists has been blessed by a clear appreciation of the biology targeted by these therapeutic agents.
因EGFR和VEGFR途径拮抗剂具有明确的靶向生物学特性，这些药物的开发受到一致好评。
VEGFR and Nasopharyr Veal carcinoma and the progress of VEGF? VEGFR applied to the therapeutic efficacy of nasopharyngeal carcinoma in recent years.
现综述近年来有关VEGF、VEGFR与鼻咽癌关系，以及VEGF、VEGFR抑制剂在鼻咽癌治疗中应用的研究进展。
The invention discloses soluble VEGFR difunctional fusion receptors, a preparation method thereof and the application thereof to antineoplastic preparation.
本发明公开了一种可溶性VEGFR双功能融合受体、其制备方法及其在 制备抗肿瘤药物中的应用。
Results VEGFR-3 was expressed in both lymphatic vessel endothelial and vessel endothelial cytoplasm, but LYVE-1 only in lymphatic vessel endothelial cytoplasm.
结果VEGFR- 3非特异地表达于微血管和淋巴管内皮细胞浆，而LYVE - 1仅特异地表达于淋巴管内皮细胞浆中。
Methods Specimens were obtained from 30 patients with rectum adenocarcinoma, and examined for the expression of VEGF-C and VEGFR-3 in carcinoma region and normal region.
方法取人直肠腺癌手术材料30例，用免疫组化方法检测癌区和癌周正常区vegf - C和VEGFR - 3的表达情况。
The positive expression rates of VEGFR-3 and VEGF-C in breast cancer with lymph node metastasis were significantly higher than that without lymph node metastasis(P<0.05);
乳腺癌组织中VEGFR-3和VEGF-C阳性表达率在有、无淋巴结转移组之间的差异均有显著性（P<0.05）；
Conclusion the overexpression of VEGF-C and VEGFR-3 in rectum adenocarcinoma may promote the hyperplasia and dilation of lymphatics, and the lymphatic metastasis of the cancer cells.
结论VEGF- C和VEGFR - 3在人直肠腺癌中的过表达，可能与淋巴管增生和扩张，促进癌细胞的淋巴转移有关。
The success of the EGFR and VEGFR pathway antagonists in treatment of metastatic NSCLC has important implications for development of novel targeted therapies such as the PKC inhibitors.
EGFR和VEGFR途径拮抗剂在治疗转移性NSCLC中的成功对开发一种新的靶向治疗药物如PKC抑制剂具有重要意义。
The neurotrophic and neuroprotective effects of VEGF are mediated via VEGFR-2, which establishes the experimental and theoretical foundation in the further treating spinal cord injures with VEGF.
通过VEGFR 2发挥神经营养和神经保护作用，为今后进一步应用VEGF治疗脊髓损伤奠定了实验及理论基础。
Objective to investigate the inhibitory effect of vascular endothelial growth factor receptor 3 (VEGFR-3) antibody on the transplantation model of human laryngeal squamous carcinoma in nude mice.
目的研究血管内皮生长因子受体3 (vascular endothelial growth factor receptor 3, VEGFR - 3)抗体对人喉鳞癌裸鼠移植瘤模型生长的抑制作用。
Methods: The expressions of VEGF-C and VEGFR-3 (Flt4) were detected by immunohistochemistry in 88 cases of rectal cancer, and their clinicopathological and clinical data were retrospectively analyzed.
方法：采用免疫组化方法检测88例直肠癌术后肿瘤组织标本中VEGF-C及VEGFR-3的表达，回顾性分析其临床病理资料。
Methods: The expressions of VEGF-C and VEGFR-3 (Flt4) were detected by immunohistochemistry in 88 cases of rectal cancer, and their clinicopathological and clinical data were retrospectively analyzed.
方法：采用免疫组化方法检测88例直肠癌术后肿瘤组织标本中VEGF-C及VEGFR-3的表达，回顾性分析其临床病理资料。
应用推荐